📰 Interim Data News
Interim Data News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Interim Data. Real-time updates on events, politics, business and more.
May 6, 2024
NEW YORK, May 6, 2024 /PRNewswire/ -- Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and...
April 9, 2024
AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...
December 12, 2023
Studies demonstrate real-world clinical utility of EsoGuard testing to detect esophageal precancer NEW YORK, Dec. 12, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. a commercial-stage, cancer...
November 15, 2023
Key Developments in FA Treatment Trials and Financial Position Strengthening
November 7, 2023
U.S. Food and Drug Administration Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia Collaboration with Eli Lilly and Company ...
September 7, 2023
Multicenter observational study documents excellent concordance of EsoGuard results with subsequent medical decision-making by multiple physicians NEW YORK, Sept. 7, 2023 /PRNewswire/ -- Lucid...
August 23, 2023
BERLIN (Reuters) -Roche inadvertently published positive lung cancer drug trial data from an interim analysis, boosting the Swiss drug maker's shares even though more data will be needed to confirm the treatment's efficacy. Roche said on Wednesday that market participants had made it aware of the inadvertent disclosure of an interim data analysis on new immunotherapy tiragolumab, part of an experimental class of drugs known as anti-TIGIT. The read-out is not yet statistically signifi...
July 28, 2023
LONDON (Reuters) -AstraZeneca Chief Executive Pascal Soriot said on Friday the company is "very encouraged" by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared results as "clinically meaningful". The drugmaker's shares fell by as much as 8% earlier this month after the company released interim data from the late-stage clinical trial called TROPION-Lung01 testing an experimental precision drug called datopotamab deru...
June 12, 2023
Omeros Corporation today announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association Congress in Frankfurt, Germany are now... | June 12, 2023
June 1, 2023
– Late-breaking abstract detailing interim data from ongoing clinical trial of OMS906 in treatment-naïve PNH patients selected for June 11, 2023 oral presentation – ... | June 1, 2023